医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

JS InnoPharm Announces First Patient Dosed with JSI-1187, a Selective ERK Inhibitor, in Phase 1 Clinical Study for Advanced Solid Tumors with MAPK Pathway Mutations

2020年07月09日 PM10:00
このエントリーをはてなブックマークに追加


 

CHICAGO & SHANGHAI

JS InnoPharm Ltd today announced the enrollment of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of JSI-1187, the company’s lead investigational drug candidate targeting the enzymes ERK1 and ERK2. The study is being conducted at 4 NCI-designated Comprehensive Cancer Centers in the U.S. JS InnoPharm holds the U.S. IND for JSI-1187, and this trial is being managed by Strategia Pharmaceuticals LLC, JS InnoPharm’s clinical development partner in the United States. Initiation of this clinical trial represents an important step in the company’s efforts to discover and develop precision medicine for cancer patients.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of JSI-1187 in patients with relapsed, refractory solid tumors with MAPK mutations. The study will comprise three components: (1) a dose escalation phase of JSI-1187 monotherapy for patients with solid tumors, (2) a dose escalation phase of JSI-1187 in combination with BRAF inhibitor, dabrafenib, and (3) an expansion phase for patients with tumors harboring specific mutations.

“JSI-1187 is a selective ERK1/2 inhibitor. By utilizing an ERK inhibitor against tumors harboring mutations in the MAPK pathway, we hope to develop more effective single-agent and combination therapies by preventing the early development of resistance seen with current MAPK targeted agents,” said Dr. Linda Paradiso, Chief Development Officer for Strategia Pharmaceuticals.

The Role of ERK in Cancer

MAPK signaling via the RAS-RAF-MEK-ERK cascade plays a critical role in cancer growth and proliferation. Alterations in the MAPK/ERK pathway are found in a variety of cancer types, with KRAS mutations in pancreatic (>90%), biliary tract (3-50%), colorectal (30-50%), lung (25-30%), ovarian (15-39%) and endometrial (18%) cancers; NRAS mutations in 20% of melanoma; and BRAF V600 mutations in 50% of melanoma and 7% of a variety of other tumor types. Although it has been demonstrated that BRAF/MEK inhibitor-targeted combination therapy provides a significant benefit beyond single agent therapy in melanoma and other cancers, the majority of patients eventually develop resistance and disease progression. Several mechanisms of acquired resistance have been identified and central to these mechanisms is the reactivation of ERK signaling. Therefore, ERK inhibition may provide the opportunity to avoid or overcome resistance from upstream mechanisms, as it is the most distal kinase of this signaling pathway.

About JSI-1187

JSI-1187 is a selective and orally administered small molecule inhibitor of ERK1 and ERK2. In preclinical studies, it demonstrated high potency against a variety of tumors with MAPK pathway mutations.

About JS InnoPharm Ltd

JS InnoPharm is a clinical stage biopharmaceutical company, dedicated to the discovery and development of novel chemical entities for cancer therapy, leveraging cutting edge knowledge in mutations, biomarkers, and precision medicine. JS InnoPharm is building an innovative pipeline by internal R&D as well as global partnering and licensing, and developing multiple clinical candidates with differential clinical strategies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005030/en/

CONTACT

Vanessa Yan

contact@jsinnopharm.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生